Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235659 | 0.88 | AKT2 (0.31) | MAPK1L3MBTL1 | |
| SCHEMBL2235551 | 0.86 | NPC1 (0.33) | ALDH1A1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2236464 | 0.85 | ALDH1A1 (0.34) | ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL27839366 | 0.81 | PNMT (0.39) | DPP4 | |
| SCHEMBL2235892 | 0.80 | DHFR (0.40) | ALDH1A1CYP2A6SMN1; SMN2 | |
| SCHEMBL16394019 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MAPK1DPP4CYP2A6HSD17B10 | |
| SCHEMBL6056117 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MAPK1DPP4CYP2A6HSD17B10 | |
| SCHEMBL2237566 | 0.74 | IKBKB (0.40) | ALDH1A1CYP2A6HSD17B10NPC1TP53 | |
| SCHEMBL2234221 | 0.74 | MEN1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15712969 | 0.73 | MAPT (0.33) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461365-B2 | Metallocene complex and polymerization method of olefin | JAPAN POLYPROPYLENE CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | JAPAN POLYPROPYLENE CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2360163-A1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | Japan Polypropylene Corporation (JP) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | ALOX12, ALOX15, ALOX15B | ALDH1A1 477/4885MAPK1 2535/4885DPP4 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.